Korea has now been added to the growing list of countries issuing new warnings about the use of gadolinium-based MRI contrast agents (GBCAs). Recently, Korea’s Ministry of Food and Drug Safety announced that it would revise the warning labels for 8 types of GBCAs, a total of 25 products. The label changes will go into effect on March 15, 2018. The ministry calls for “careful discretion” when considering the use of GBCAs. This is based on observations of accumulation, particularly of a type called Gadobutrol, in the areas of the brain called the globus pallidus and the cerebellar dentate nucleus in patients who have had multiple gadolinium-based contrast injections. The respective revisions include contrast agents developed by Bracco Imaging Korea, GE Healthcare AS Korea, Bayer Korea, Taejoon Pharm, Guerbet Korea, Dai Han Pharm, Dongkook Pharmaceutical, Imaging Solutions Korea, and Dasol Life Science. For more information, visit http://www.koreabiomed.com/news/articleView.html?idxno=2679 Please join the growing list of advocates and sign our petition so we can help promote the development of safer alternatives and effective treatments to remove gadolinium from patients affected by it.